Nazartinib; EGF816; NVS-816

Lebitso la lik'hemik'hale:

(R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)- 2-methylisonicotinamide

SMILES Khouto:

O=C(NC1=NC2=CC=CC(Cl)=C2N1[C@H]3CN(C(/C=C/CN(C)C)=O)CCCC3)C4=CC=NC(C)= C4

Khoutu ea InChi:

InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33( 26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5, 8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1

InChi Key:

IOMMMLWIABWRKL-WUTDNEBXSA-N

Keyword:

Nazartinib ,EGF816, EGF-816, EGF 816, NVS-816, 1508250-71-2

Sollubility:E qhibiliha ka DMSO

Polokelo:0 - 4 ° C bakeng sa nako e khutšoanyane (matsatsi ho isa libeke), kapa -20 ° C bakeng sa nako e telele (likhoeli)

Tlhaloso:

Nazartinib, eo hape e tsejoang e le EGF816 le NVS-816, ke inhibitor e fumanehang ka molomo, e ke keng ea fetoloa, ea moloko oa boraro, e khethiloeng ke epidermal growth factor receptor (EGFR) inhibitor, e nang le ts'ebetso e ka bang teng ea antineoplastic. EGF816 ka kopanelo e tlama le ho thibela ts'ebetso ea mefuta e feto-fetohileng ea EGFR, ho kenyeletsoa T790M EGFR mutant, ka tsela eo e thibela pontšo ea EGFR-mediated. Sena se ka 'na sa baka lefu la sele le ho thibela kholo ea hlahala ho EGFR-overexpressing tumor cell. EGF816 ka ho khetheha e thibela mefuta e fetotsoeng ea EGFR e kenyelletsang T790M, phetoho ea bobeli e fumanoeng ea ho hanyetsa, 'me e ka ba le melemo ea phekolo ho lihlahala tse nang le khanyetso ea T790M ha li bapisoa le tse ling tsa EGFR tyrosine kinase inhibitors.

Sepheo: EGFR